Agents that activate cyclic AMP-dependent protein kinase inhibit explant culture growth and mitotic activity.
Epidermal cells contain 4 separate surface receptors which are linked to adenylate cyclase. Activation of any one of these receptors leads to the accumulation of cAMP within the cell which in turn leads to the activation of cAMP-dependent protein kinase. The levels of cAMP accumulation within the cell caused by the 4 activators are not the same. Epinephrine, histamine, adenosine, and prostaglandins of the "E" series cause easily measurable concentrations of cAMP within 5 min of exposure. Prostaglandin F2 alpha causes only a small nonsignificant increase. Similarly, 2 phosphodiesterase inhibitors, which inhibit the breakdown of cAMP formed within the cell, differ in their ability to accumulate cAMP when cells are exposed to these agents alone. Isobutylmethylxanthine causes a measurable increase in cAMP, while theophylline, a weak inhibitor of phosphodiesterase, gives a nonsignificant increase in cAMP. Recently, experiments have shown that agents that give only slight increases in cAMP by biochemical measurements, that is, prostaglandins F2 alpha and theophylline, are equally able to activate protein kinase within the cell. Since activation of protein kinase is the only mechanism for an increase in cAMP to have a physiologic effect, all of these agents that do activate protein kinase should cause physiologic effects. Using an explant culture system, we show in this paper that this supposition is correct and that all agents that activate protein kinase do result in inhibition of mitotic activity regardless of whether or not they are able to raise cAMP to a level that can be biochemically measured as being significantly different from the baseline value.
D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology; D000241:Adenosine / Q000494:pharmacology; D000818:Animals; D002455:Cell Division / Q000187:drug effects; D046508:Culture Techniques; D000242:Cyclic AMP / Q000494:pharmacology*; D015237:Dinoprost; D015232:Dinoprostone; D004789:Enzyme Activation; D004837:Epinephrine / Q000494:pharmacology; D006632:Histamine / Q000494:pharmacology; D008938:Mitosis / Q000187:drug effects*; D011458:Prostaglandins E / Q000494:pharmacology; D011460:Prostaglandins F / Q000494:pharmacology; D011494:Protein Kinases / Q000378:metabolism*; D012867:Skin / Q000166:cytology* / Q000201:enzymology; D013552:Swine; D013806:Theophylline / Q000494:pharmacology
D011458:Prostaglandins E; D011460:Prostaglandins F; D006632:Histamine; D015237:Dinoprost; D013806:Theophylline; D000242:Cyclic AMP; D011494:Protein Kinases; D000241:Adenosine; D015232:Dinoprostone; D015056:1-Methyl-3-isobutylxanthine; D004837:Epinephrine